Bringing the fundamentals into focus…
Back to Pacira BioSciences, Inc.
How Pacira BioSciences, Inc. stacks up
PCRX · against 1,336 other Healthcare companies
Valuation
53/ 100
Above the middle of the pack.
Ranked #623 of 1,337 · scores higher than 53% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 50–59, including PCRX · Click a bar to see the companies
Why valuation scores 53?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Earnings yield is close to the peer norm. Earnings yield: 1.0% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 72% of peers. EBITDA yield: 6.7% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 95% of peers. Free cash flow yield: 12.4% vs peer median 0.0%
Metric by metric
Position: dot = PCRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PCRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 1.0% | 1.5% | 45% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 7.7% | 4.2% | 72% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 12.4% | -1.0% | 95% | 20% | |
| Book yieldHigher is better · 1,306 reported | 46.4% | 37.9% | 60% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PCRX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 623 | 161.8B USD | 53 | 50 | |
| 623 | 2.6B USD | 53 | 66 | |
| 623 | 5.5B USD | 53 | 43 | |
| 623 | 14.6B USD | 53 | 59 | |
| 623 | 1.5B USD | 53 | 59 | |
| 623 | 759M USD | 53 | 54 | |
| 623 | 1.6B USD | 53 | 48 | |
| 623 | 258.2B USD | 53 | 47 | |
| 636 | 4.2B CNY (≈$590M) | 52 | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score